| OR (95% CI)a | OR (95% CI)b | OR (95% CI)c |
---|
Validation cohort A | 1.62 (1.18–2.21)# | 1.58 (1.15–2.15)# | 1.51 (1.09–2.08)* |
Validation cohort B | 1.96 (0.54–7.25) | 2.32 (0.63–8.52) | 1.51 (0.36–6.38) |
- Validation cohort A: FSGS + MCD (N = 157)
- Validation cohort B: MN (N = 59)
- Renal outcome defined as no response to therapy
- β2-microglobulin; uCr: urinary creatinine
- a Adjusted by age, gender and clinical parameters (eGFR)
- b Adjusted by age, gender and pathological parameters (global sclerosis, segmental sclerosis, interstitial fibrosis, inflammatory cell infiltration and tubular atrophy)
- c Adjusted by age, gender, clinical parameters (eGFR) and pathological parameters (global sclerosis, segmental sclerosis, interstitial fibrosis, inflammatory cell infiltration and tubular atrophy)
- *P < 0.05, #P < 0.01